October 2008
Worldwide Biotech;Oct2008, Vol. 20 Issue 10, p5
Trade Publication
The article deals with the impact of cost containment measures of governments and payers on new drug development. A example is given of the rejection by Britain's National Institute of Clinical Excellence (NICE) of four new kidney cancer therapies on the basis of cost effectiveness. The efforts to reduce healthcare costs are said to put pressure on pharmaceutical companies. It was noted that drug companies will find it more difficult to make a profit if innovative drugs are not launched in the near future.


Related Articles

  • NICE says no to kidney cancer drugs, sparks uproar.  // PharmacoEconomics & Outcomes News;8/23/2008, Issue 560, p2 

    The article reports that the National Institute of Clinical Excellence (NICE) in Great Britain found that bevacizumab, sorafenib, sunitinib and temsirolimus are not cost effective. Because of the this, the kidney cancer drugs will not be provided by the National Health Service (NHS) to patients...

  • NICE and NHS England propose "fast-track" process.  // PharmacoEconomics & Outcomes News;10/22/2016, Vol. 764 Issue 1, p35 

    The article reports ont he proposed fast-track option for appraising cost-effective treatments and promotion of cost per quality-adjusted life-year program for patients, by the British National Institute for Health and Care Excellence (NICE) and National Health Service (NHS) in Great Britain.

  • When the price is right.  // Nature Biotechnology;May2006, Vol. 24 Issue 5, p473 

    The article focuses on the decision of the National Institute of Clinical Excellence (NICE) to reject a newly approved biotechnology drug in Great Britain. NICE did not deny the efficacy of the drug in question nor deny that it could bring significant benefit to a subset of diabetes sufferers,...

  • Genentech/Roche: UK's NICE remains negative over Avastin for colorectal cancer.  // PharmaWatch: Monthly Review;Jan2010, Vol. 9 Issue 1, p7 

    The article reports on the decision of the National Institute for Clinical Excellence (NICE), the cost effectiveness watchdog in Great Britain, to reject the use of Avastin with chemotherapy for treating first-line colorectal cancer patients. It argues that the drug is not a cost effective use...

  • Feature Analysis.  // PharmaWatch: CNS;Mar2007, Vol. 6 Issue 3, p19 

    The article reports on the compliance of physicians to the guidelines set by the National Institute for Clinical Excellence (NICE) regarding the use of cognitive enhancers for Alzheimer's disease in Breat Britain. The use of cognitive enhancers have been restricted by NICE citing high cost as...

  • Referral costs cut by NICE urinary symptom advice.  // GP: General Practitioner;6/24/2011, p16 

    The article discusses results of a survey of 201 General Practitioners (GP) which has found that eight in 10 GPs who follow guidelines of the National Institute of Clinical Excellence (NICE) experience reduction in the cost of referral to secondary care. It has been stated that the survey found...

  • NICE's threshold for end-of-life, life-extending interventions?  // PharmacoEconomics & Outcomes News;11/26/2011, Issue 642, p2 

    The article reports on an increase in the British National Institute for Clinical Excellence's (NICE) incremental cost-effectiveness ratio (ICER) threshold for life-extending, end-of-life interventions, according to investigators from Costello Medical Consulting Ltd.

  • Experts defend NICE against attack by US politician. Kmietowicz, Zosia // BMJ: British Medical Journal (International Edition);11/25/2006, Vol. 333 Issue 7578, p1087 

    The article focuses on the reaction of British educators and medical authorities to criticism of Great Britain's National Institute for Health and Clinical Excellence (NICE), by Alex Azar, the secretary of health for the United States. The criticism was concerned with NICE's decision to ration...

  • From Research to Health Care Practice: How the UK Uses Data on Comparative Effectiveness. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;9/8/2010, Vol. 304 Issue 10, p1058 

    An interview with Kalipso Chalkidou, director of the international program at Great Britain National Institute of Clinical Excellence (NICE), is presented. She explains the reasons for creating NICE, along with how NICE fulfills it mission of improving care and efficiency in the country. She...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics